Researchers looked at how the medication fingolimod affects children with multiple sclerosis (Ped-MS). They analyzed data from 585 patients over a period of about 24 months to see how the treatment changed their condition compared to their status before starting the medicine.
The results showed that patients taking fingolimod had a significant decrease in their annualized relapse rate. Specifically, there was a reduction of 1.17 relapses per patient-year. While the medication helped reduce these relapses, it did not show a statistically significant change in the Expanded Disability Status Scale (EDSS), which measures physical disability.
Most patients, about 79.8 percent, stayed on the medication for nearly two years. Some common side effects reported during treatment included headache, cough, infections, and low white blood cell counts. Because this was a meta-analysis of existing data, it provides a broad look at the drug's performance but does not replace a personal consultation with a doctor to determine the best treatment plan.
Common questions
How effective is fingolimod for children with multiple sclerosis?
The study showed that fingolimod significantly reduced the annualized relapse rate in children. Patients saw a decrease of 1.17 relapses per patient-year compared to their baseline. While it helped reduce these relapses, it did not show a significant change in the Expanded Disability Status Scale (EDSS) during the 24-month period.
What are the common side effects of fingolimod?
Patients taking fingolimod reported some common side effects, including headache and cough. Other reported issues included infections and low white blood cell counts (leukopenia or lymphopenia). You should talk to a doctor to discuss how these risks apply to your specific situation.
How many children stayed on the medication during the study?
The data showed that approximately 79.8 percent of patients remained on fingolimod after nearly 24 months of treatment. This suggests that a large majority of the children in the study were able to continue with the therapy for at least two years.
